Citation

Pompili M, Orsolini L, Lamis DA, Goldsmith DR, Nardella A, Falcone G, Corigliano V, Luciano M, Fiorillo A. CNS Neurol. Disord. Drug Targets 2017; 16(4): 454-462.

Affiliation

Department of Psychiatry, University of Naples SUN, Naples, Italy.

Copyright

(Copyright © 2017, Bentham Science Publishers)

DOI

10.2174/1871527316666170223163629

PMID

28240189

Abstract

Suicide risk is a major cause of death among patients with schizophrenia. Death by suicide has been reported in approximately 5% of schizophrenia patients although such figure appears an underestimation of the problem. A number of risk factors are routinely reported as associated with suicide risk among these patients, some of which are modifiable by targeted therapeutic strategies. Clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. Long-Acting Injectable Antipsychotics (LAIs) have a range of advantages in terms of efficacy, safety and tolerability in the treatment of schizophrenia, and one area of interest is whether LAI-treatment may decrease suicidality by indirectly acting on a range of risk factors for suicide specific to schizophrenia patients. This background encouraged the present, review of research pertaining to LAI in relation to modifiable risk factors for suicide in schizophrenia. We viewed our task as gathering, speculatingand critically appraising the available research relevant to the topic, with the aim of formulating a hypothesis to be tested with further research.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Language: en

Keywords

Long-Acting Injectable Antipsychotics; prevention; schizophrenia; suicide